Efficacy of Triple-Drug Therapy to Prevent Pancreatic Fistulas in Patients With High Drain Amylase Levels After Pancreaticoduodenectomy.
Adult
Aged
Aged, 80 and over
Amylases
/ analysis
Carbapenems
/ therapeutic use
Drug Therapy, Combination
Gabexate
/ therapeutic use
Humans
Middle Aged
Octreotide
/ therapeutic use
Pancreatic Fistula
/ etiology
Pancreaticoduodenectomy
/ adverse effects
Postoperative Complications
/ prevention & control
Retrospective Studies
Drain amylase level
PD
PF
TDT
Journal
The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
01
03
2018
revised:
21
07
2018
accepted:
03
08
2018
entrez:
12
12
2018
pubmed:
12
12
2018
medline:
14
11
2019
Statut:
ppublish
Résumé
Prior studies have suggested that drain amylase level is a predictive marker for developing pancreatic fistulas (PFs) after pancreaticoduodenectomy (PD). However, means of preventing PF after discovering high drain amylase levels have not been previously established. The purpose of this study was to evaluate the efficacy of a combination drug therapy (using three drugs; gabexate mesilate, octreotide, and carbapenem antibiotics, named as triple-drug therapy [TDT]) regimen in preventing PF for patients with high drain amylase levels on postoperative day (POD) 1 after PD. We divided the 183 patients who underwent PD into two groups in accordance with their enrollment in the study: for those enrolled early in the study (early period), TDT was not administered to patients with high drain amylase level; however, for those enrolled later in the study (late period), TDT was administered if drain amylase levels were over 10,000 IU/L on POD 1. We retrospectively compared the incidence of PF between the two groups. Incidences of PFs were statistically, significantly prevented in the late group (early 17% versus late 6%; P = 0.01). For patients with low levels of drain amylase (<10,000 IU/L), the PF ratio was equivalent between two groups (early 8% versus late 5%; P = 0.56); however, PFs in patients with high drain amylase levels in the late period group were dramatically prevented by TDT administration (early 89% versus late 11%; P < 0.001). TDT may be a promising therapy to prevent PFs in patients with high drain amylase levels after PD.
Sections du résumé
BACKGROUNDS
Prior studies have suggested that drain amylase level is a predictive marker for developing pancreatic fistulas (PFs) after pancreaticoduodenectomy (PD). However, means of preventing PF after discovering high drain amylase levels have not been previously established. The purpose of this study was to evaluate the efficacy of a combination drug therapy (using three drugs; gabexate mesilate, octreotide, and carbapenem antibiotics, named as triple-drug therapy [TDT]) regimen in preventing PF for patients with high drain amylase levels on postoperative day (POD) 1 after PD.
MATERIALS AND METHODS
We divided the 183 patients who underwent PD into two groups in accordance with their enrollment in the study: for those enrolled early in the study (early period), TDT was not administered to patients with high drain amylase level; however, for those enrolled later in the study (late period), TDT was administered if drain amylase levels were over 10,000 IU/L on POD 1. We retrospectively compared the incidence of PF between the two groups.
RESULTS
Incidences of PFs were statistically, significantly prevented in the late group (early 17% versus late 6%; P = 0.01). For patients with low levels of drain amylase (<10,000 IU/L), the PF ratio was equivalent between two groups (early 8% versus late 5%; P = 0.56); however, PFs in patients with high drain amylase levels in the late period group were dramatically prevented by TDT administration (early 89% versus late 11%; P < 0.001).
CONCLUSIONS
TDT may be a promising therapy to prevent PFs in patients with high drain amylase levels after PD.
Identifiants
pubmed: 30527504
pii: S0022-4804(18)30581-X
doi: 10.1016/j.jss.2018.08.016
pii:
doi:
Substances chimiques
Carbapenems
0
Gabexate
4V7M9137X9
Amylases
EC 3.2.1.-
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-83Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.